• B cells;
  • CD22;
  • genetics;
  • polymorphism;
  • systemic sclerosis


Activating and inhibitory signal transducers, CD19 and CD22, have been substantially implicated both in human systemic sclerosis (SSc) and tight-skin mouse, a model for SSc. We previously showed that a single nucleotide polymorphism (SNP) in CD19 promoter region was significantly associated with increased CD19 expression level and with susceptibility to SSc. In the present study, we examined whether CD22 polymorphisms were associated with susceptibility to SSc. CD22 variations were genotyped in 126 Japanese patients with SSc [47 diffuse cutaneous SSc and 79 limited cutaneous SSc (lcSSc)] and 93 unrelated healthy controls. At the c.2304C > A SNP coding for a synonymous substitution in exon 13, A/A genotype was observed in six patients with SSc (4.8 %) but none in the controls (P = 0.040). All six patients with A/A genotype belonged to the lcSSc subgroup (7.6%, P = 0.008 vs controls). Surface expression level of CD22 tended to be lower in B cells from the patients with A/A genotype (n = 5) as compared with C/A (n = 7) or C/C (n = 14) genotype (17% decrease, P = 0.0032). Taken together with our previous observation on CD19 polymorphism, intrinsic difference in the expression level of CD19 and CD22 was suggested to play a causative role in a proportion of patients with lcSSc.